Mehr lesen
Der Band zeichnet die oft spektakulären Erfolgs- oder Misserfolgsgeschichten neuartiger pharmazeutischer Wirkstoffe nach und nimmt den Leser dabei mit auf die Reise von den ersten Anfängen der Heilkunde bis zum Milliardengeschäft der modernen Pharmaindustrie. Sachkundig geschrieben, reich illustriert, anregend: Eine unterhaltsame Lektüre!
Inhaltsverzeichnis
Foreword
Preface and Acknowledgment
EVOLUTION OF DRUG DISCOVERY
Antiquity
Great Periods of Drug Discovery
Vaccines
THE FIRST SYNTHETIC DRUGS AND THE BIRTH OF CHEMOTHERAPY
Aspirin, Phenacetin, and Paracetamol
Discovery of Pyrazolones
Cocaine and Local Anesthetics
Barbiturates and Related Compounds
Fathers of Chemotherapy
FROM CASUAL OBSERVATIONS TO SYSTEMATIC SEARCH
From Antihistamines to Antipsychotics and Antidepressants: The Origins of Psychopharmacology
Benzodiazepines
Structural Variations on Sulfanilamide
Azoles as a Source of Antibacterials, Antifungals, and Antihelmintics
The Long Fight Against Cancer
Sildenafil - The First Inhibitor of Rectile Dysfunction
NATURE AS A SOURCE OF DRUGS: DRUGS FROM NATURAL PRODUCTS
Plant Sources: Derivatives and Related Drugs (Selected Examples)
Animal Sources: Derivatives and Related Drugs
Drugs from Microbiological Sources
Drugs from Marine Origin: The Contribution of the Sea to the Therapeutic Arsenal
RATIONALIZING THE DRUG DISCOVERY PROCESS
Early Rational Drug Discovery Approaches: L-Dopa and L-Alpha-Methyldopa
Receptor-Based Drug Discovery
Antimetabolites in the Fight Against Bacteria, Viruses, and Cancer
Cyclooxygenase(COX) Inhibitors
STRUCTURE-BASED DRUG DISCOVERY
Searching for the Ideal Antihypertensive Agent: Renin-Angiotensin-Aldosterone System (RAAS)
HIV Protease Inhibitors
Drugs Effective Against the Influenza Virus (the Flu)
Fight Against Cancer
New Avenues for the Development of Antidiabetic Agents. Dipeptidyl-Peptidase-IV Inhibitors: Sitagliptin and Vildaglptin
BIOPHARMACEUTICALS
Monoclonal Antibodies (MAbs)
Recombinant DNA Technology (Genetic Engineering)
Some Recombinant Protein Drugs
Protein-Polyethyleneglycol (PEG) Conjugates (Protein PEGylation)
DRUG DISCOVERY IN THE POSTGENOMIC ERA: CONCLUDING REMARKS
Chemical/Genomic Strategy
Summary
Über den Autor / die Autorin
Enrique Ravina holds the chair for Pharmaceutical Organic Chemistry at the University of Santiago de Compostela (Spain). He was trained as a organic chemist and has a lifetime of experience in pharmaceutical chemistry, most prominently in the area of antipsychotic and cardiovascular drugs. He is a member of the Spanish Royal Academy of Pharmacy, a founding member of the Spanish Society of Medicinal Chemistry, and a member of the American Chemical Society. In 2008, he has published a highly acclaimed book on the history of drugs and their discovery in Spain (published in Spanish language).
Zusammenfassung
Der Band zeichnet die oft spektakulären Erfolgs- oder Misserfolgsgeschichten neuartiger pharmazeutischer Wirkstoffe nach und nimmt den Leser dabei mit auf die Reise von den ersten Anfängen der Heilkunde bis zum Milliardengeschäft der modernen Pharmaindustrie. Sachkundig geschrieben, reich illustriert, anregend: Eine unterhaltsame Lektüre!
Bericht
"This serves as an excellent companion to many of the popular medicinal chemistry and pharmacology books, and gives students additional insight into the contemporary drug discovery process." (Doody s, 16 March 2012)
"The text is well referenced and complete with chemical illustrations. . . Recommended. Upper-division undergraduates through professionals." (Choice, 1 October 2011)
"It can be used by students interested in the classic achievements and case stories of drug discovery, but also by more experienced scientists as a guiding overview on the field. Last but not least, it serves well as a compendium to industrial professionals in the field of biomedical and medicinal chemistry research." (ChemMedChem, 2011)
